Axitinib is a targeted therapy drug used in the treatment of metastatic renal cell carcinoma (RCC). It works to block certain proteins, known as vascular endothelial growth factor receptors (VEGFRs), from growing and spreading. This allows for improved outcomes in patients with this form of cancer. However, like other treatments, there are risks and side effects associated with its use. In this article, we will discuss what you need to know about axitinib in order to make informed decisions about your treatment plan. We will explore how it works, the different types available, common side effects associated with use, and other important information that can help you feel confident in your choice of treatment.
Axitinib is a targeted cancer therapy that works by inhibiting the activity of tyrosine kinase enzymes. These enzymes are involved in the growth and spread of cancer cells. Axitinib is used to treat renal cell carcinoma (RCC), a type of kidney cancer. It is typically used after other treatments, such as surgery, have failed. Axitinib may also be used to treat other types of cancers, such as thyroid cancer or non-small cell lung cancer (NSCLC).
Axitinib belongs to a class of drugs known as kinase inhibitors. Kinase inhibitors work by blocking the activity of certain enzymes, which can help stop the growth and spread of cancer cells. Axitinib is a targeted therapy, which means it targets specific molecules that are involved in the growth and spread of cancer cells. Axitinib inhibits the activity of tyrosine kinase enzymes. These enzymes are found in healthy cells, but they are overactive in cancer cells. By inhibiting these enzymes, axitinib can help stop the growth and spread of cancer cells.
Axitinib works by inhibiting the vascular endothelial growth factor (VEGF) receptor. This protein is responsible for the growth and development of new blood vessels. When the VEGF receptor is inhibited, blood vessel growth is prevented, which in turn slows down the growth of cancerous tumors. Axitinib has been shown to be effective in treating several types of cancer, including renal cell carcinoma, gastrointestinal stromal tumor, and thyroid cancer.
The most common side effects of Axitinib are diarrhea, fatigue, high blood pressure, loss of appetite, and nausea. Less common side effects include bleeding, brain hemorrhage, heart attack, kidney failure, and liver damage. Some of the more rare side effects include hair loss, skin rash, and vision changes.
If you miss a dose of axitinib, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Axitinib is a powerful cancer-fighting drug that can be used to treat certain types of tumors. While the side effects and risks associated with its use must always be taken into account, it has been proven effective in many cases. With careful monitoring and guidance from your oncologist or hematologist, axitinib can be incorporated into an individualized treatment plan that helps you manage your disease while minimizing any potential adverse reactions.
1.
An individual state lost $4.02 billion due to untreated mental illness.
2.
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
3.
Black Canadians Face Multiple Barriers to Blood Donation
4.
Study: Discovery of cellular identity may influence cancer treatment
5.
Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer
1.
Drug Safety Through Oncology Survivorship Medication Monitoring Frameworks
2.
Digital Oncology Navigation Systems for Coordinated Multidisciplinary Cancer Care
3.
Simulation for Hematology Emergencies: Enhancing Clinical Preparedness and Patient Outcomes
4.
Colon Cancer Staging: What You Need to Know
5.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
How Multidisciplinary Teams Support Modern Cancer Care
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part VIII
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation